3D Medicines (HKSE:01244) Capex-to-Operating-Cash-Flow : 0.03 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

3D Medicines's Capital Expenditure for the six months ended in Dec. 2023 was HK$-0.83 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$25.93 Mil.

Hence, 3D Medicines's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.03.

3D Medicines Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for 3D Medicines's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Capex-to-Operating-Cash-Flow Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Cash-Flow

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial			-	-	-	-	0.03

Competitive Comparison of 3D Medicines's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, 3D Medicines's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3D Medicines's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Capex-to-Operating-Cash-Flow falls into.

3D Medicines Capex-to-Operating-Cash-Flow Calculation

3D Medicines's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (-6.917)	/	-157.956
	=	N/A

3D Medicines's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow	=	- Capital Expenditure	/	Cash Flow from Operations
	=	- (-0.825)	/	25.925
	=	0.03

3D Medicines (HKSE:01244) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

3D Medicines Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Capex-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines